A preclinical study of allogeneic CD19 chimeric antigen receptor double‐negative T cells as an off‐the‐shelf immunotherapy drug against B‐cell malignancies

• Published in: Clinical & translational immunology Vol. 13; no. 12; pp. e70022 - n/a
• Main Authors: Wang, Dan, Wang, Liuyang, Liu, Shuai, Tong, Jianjun, Zhu, Honglin, Xu, Man, Li, Xiancai, Xiang, Zhiqiang, Sun, Qinghua, Wang, Hengcai, Wang, Yuli, Wang, Shuyang, Yang, Liming
• Format: Journal Article
• Language: English
• Published: Australia John Wiley & Sons, Inc 2024; John Wiley and Sons Inc; Wiley
• Subjects: allogeneic CD19‐CAR‐DNTs; Allografts; Antibodies; Antigens; Antitumor activity; Blood cancer; B‐cell malignancies; Cancer; CD19 antigen; Cell culture; Cell survival; Cell viability; Cells; Chimeric antigen receptors; Cryopreservation; Cytotoxicity; cytotoxicity and safety; Expression vectors; Flow cytometry; Genotype & phenotype; Graft versus host disease; Graft-versus-host reaction; Immunotherapy; Immunotoxicity; Ligands; Lymphocytes; Lymphocytes T; Lymphoma; Malignancy; Manufacturing; Nitrogen; off‐the‐shelf immunotherapy; Original; Proteins; Proteomes; Tumors; Xenografts; cytotoxicity and safety; B‐cell malignancies; off‐the‐shelf immunotherapy; allogeneic CD19‐CAR‐DNTs

Objectives To evaluate the manufacturability, efficacy and safety of allogeneic CD19 chimeric antigen receptor double‐negative T cells (CD19‐CAR‐DNTs) as an off‐the‐shelf therapeutic cell product. Methods A membrane proteome array was used to assess the off‐target binding of CD19‐CAR. DNTs derived f...